ResultsIQ

ResultsIQ › Latest results › Jubilant Ingrevia Limited

Jubilant Ingrevia Limited Q1 FY27 results press release summary

NSE: JUBLINGREA · BSE: 543271

Results press release of 22 Jul 2026, summarised by AI from the filing.

Growth led by Specialty Chemicals and Nutrition, with sequential improvement in revenue and EBITDA over coming quarters.

Key takeaways

  1. FY27 guidance Growth led by Specialty Chemicals and Nutrition, with sequential improvement in revenue and EBITDA over coming quarters.
  2. Chemical Intermediates rebound Segment EBITDA ₹57 cr, up 240% YoY and 163% QoQ, on realization gains and cost pass-through.
  3. CDMO pipeline Funnel of 100+ molecules with ₹3500+ cr peak revenue potential; 25+ confirmed molecules.

Original filing on BSE

Jubilant Ingrevia Limited Q1 FY27 results

As filed: Revenue ₹1,300 cr (+25% year on year), EBITDA ₹199 cr (+39% year on year), PAT ₹106 cr (+41% year on year), EBITDA margin 15.3% (+154 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,179 cr (+12% year on year), EBITDA ₹163 cr (+11% year on year), PAT ₹86.4 cr (+17% year on year), EBITDA margin 13.8% (−19 bps). Score 65 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 19 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −5.5% in 29 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹1,051 cr (−1% year on year), EBITDA ₹127 cr (−9% year on year), PAT ₹46.9 cr (−18% year on year), EBITDA margin 12.0% (−111 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit before exceptional items growth were below it. EBITDA margin fell 111 bps year on year. Revenue fell 6% from last quarter. Share price after the results: −7.0% in 30 days (Nifty 500: +1.2%).
  • Q2 FY26: Revenue ₹1,121 cr (+7% year on year), EBITDA ₹135 cr (+8% year on year), PAT ₹69.0 cr (+17% year on year), EBITDA margin 12.0% (+8 bps). Score 49 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin was flat year on year. Consolidated profit +17% but standalone -27%. Profit fell 8% from last quarter. Share price after the results: −4.6% in 30 days (Nifty 500: +2.3%).
  • Q1 FY26: Revenue ₹1,038 cr (+1% year on year), EBITDA ₹143 cr (+31% year on year), PAT ₹75.0 cr (+53% year on year), EBITDA margin 13.8% (+313 bps). Score 60 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 313 bps year on year. Share price after the results: −10.5% in 29 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹1,051 cr (−2% year on year), EBITDA ₹147 cr (+62% year on year), PAT ₹74.0 cr (+155% year on year), EBITDA margin 14.0% (+551 bps). Score 75 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 551 bps year on year. Share price after the results: +4.5% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹1,057 cr (+9% year on year), EBITDA ₹139 cr (+46% year on year), PAT ₹69.0 cr (+77% year on year), EBITDA margin 13.2% (+332 bps). Score 88 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 332 bps year on year.
  • Q2 FY25: Revenue ₹1,045 cr (+2% year on year), EBITDA ₹125 cr (+6% year on year), PAT ₹59.0 cr (+4% year on year), EBITDA margin 12.0% (+39 bps). Score 39 of 100, Below trend. EBITDA margin rose 39 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Jubilant Ingrevia Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.